BioWorld: With a howl and a series A, Werewolf Therapeutics is born
Even though November’s full moon had come and gone more than a week previous, Werewolf Therapeutics Inc. came out of the shadows Wednesday with a $56 million series A fundraiser to state its plans to develop immune-stimulatory therapeutics to trigger immune responses to cancer.



By Lee Landenberger